Novel small molecules inhibit cancer-associated enzymes in cells
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
Researchers have discovered compounds able to restart production of VEGF-A in cellular models, which rebuilds blood vessels and muscle in damaged heart tissue.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
A molecule called TPPU has been shown to inhibit an enzyme that plays a key role in inflammation, successfully treating arthritis in mice.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.